Vendor, Salisbury, GBR
Ministry of Defence
UEI U6LDUQKZ2CS8, CAGE KB887
8 awards and $9,944,632 obligated between January 10, 2024 and July 21, 2026, 100% under full and open competition, against 36.0 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Defense Threat Reduction Agency | $10,032,062 |
| Office of Assistant Secretary for Preparedness and Response | $0 |
| National Institutes of Health | $0 |
| Food and Drug Administration | -$87,430 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $6,125,409 |
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $3,942,100 |
| Biological Product (except Diagnostic) ManufacturingNAICS 325414 | $0 |
| Professional, Scientific, and Technical ServicesNAICS 541712 | -$122,877 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 8 |
| Definitive Contract | 6 |
| Delivery Order | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HDTRA124C0008Definitive Contract, June 6, 2024, Full and Open Competition, 1 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | Generation of a Novel Antibody-Antibiotic Conjugate as a Combination Therapy Platform to Treat Melioidosis or Plague.NAICS 541714, PSC AC32 | $5,630,591 |
| HDTRA122C0032Definitive Contract, April 18, 2024, Full and Open Competition, 1 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | Non Ionic Surfactant Vesicles (Nisvs) as a Drug Delivery and Targeting System for Antimicrobials.NAICS 541715, PSC AC32 | $3,432,068 |
| HDTRA122C0035Definitive Contract, March 4, 2024, Full and Open Competition, 21 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | Research and Development on Deep Learning Development and Evaluation Framework.NAICS 541715, PSC AC31 | $510,033 |
| HDTRA120C0016Definitive Contract, January 10, 2024, Full and Open Competition, 152 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | Pharmacological and Biologic Intervention to Reduce Inflammation and Seizures Caused by Viral EncephalitisNAICS 541714, PSC AD93 | $494,818 |
| HHSO10033001TDelivery Order, November 26, 2024, Full and Open Competition, 3 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Close This Task Order. Awarded to the Defence Science and Technology Laboratory (Dstl), UK Is Issued to Characterize a NON-HUMAN Primate ModNAICS 325414, PSC AN13 | $0 |
| 75N93024D00010July 10, 2024, Full and Open Competition, 76 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | Pre-Clinical Models of Infectious Diseases - Task Areas a and BNAICS 541714, PSC AN11 | $0 |
| HDTRA117C0028Definitive Contract, July 18, 2024, Full and Open Competition, 19 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | Crystalcast ToolsetNAICS 541712, PSC AD92 | -$35,447 |
| HHSF223201510066CDefinitive Contract, October 24, 2024, Full and Open Competition, 15 offers | FDA Office of Acq Grant SVCSFood and Drug Administration | BAA Contract Titled, "determination of the Efficacy of Antibiotics Against Melioidosis Acquired by Different Routes of Infection."NAICS 541712, PSC AZ11 | -$87,430 |
- Product and service codes
- AC32 National Defense R&D Services; Defense-Related Activities; Applied ResearchAC31 National Defense R&D Services; Defense-Related Activities; Basic ResearchAD93 AN11 Health R&D Services; Health Care Services; Basic ResearchAN13 Health R&D Services; Health Care Services; Experimental DevelopmentAD92
- Transactions
- 35 across 8 awards